About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

At its Sept. 14, 2026 interim results briefing, Xinqi Microelectronics said deliveries are secured via multi-sourcing and strategic stockpiles, with the overall supply chain currently stable and major supply risks controllable. The company will incre

2026-09-14

At its Sept. 14, 2026 interim results briefing, Xinqi Microelectronics said deliveries are secured via multi-sourcing and strategic stockpiles, with the overall supply chain currently stable and major supply risks controllable. The company will increase qualification and adoption of Chinese-made components to further strengthen supply‑chain resilience.

Other News
2026-09-14

1. Nagen Technology (09856.HK): Plans to issue 172 million H shares in its Hong Kong listing at HK$32.96 per share. 2. R&F Properties (02777.HK): Total sales revenue for the first eight months was approximately RMB 8.85 billion, a decrease of 5.85%

1. Nagen Technology (09856.HK): Plans to issue 172 million H shares in its Hong Kong listing at HK$32.96 per share. 2. R&F Properties (02777.HK): Total sales revenue for the first eight months was approximately RMB 8.85 billion, a decrease of 5.85% year-on-year. 3. Hengrui Medicine (01276.HK): Its injectable drug, Ruzetatopramab, has been included in the Breakthrough Therapy Product List. 4. Zhongliang Holdings (02772.HK): Cumulative contracted sales for the first eight months were approximately RMB 4.29 billion, a decrease of 48.25% year-on-year. 5. Seazen Holdings (01030.HK): Cumulative contracted sales for the first eight months were approximately RMB 8.107 billion, a decrease of 40.24% year-on-year. 6. Global Digital Holdings (00339.HK): Plans to place up to 86.4 million shares at a discount of approximately 18.25%, raising net proceeds of approximately HK$46.76 million. 7. China Biopharmaceutical (01177.HK) plans to acquire a 5% stake in Chia Tai Tianqing Pharmaceutical Group from Xie Chengrun for RMB 4.48 billion, increasing its indirect shareholding to 65% upon completion. 8. Hansoh Pharmaceutical (03692.HK): Its injectable levotartrazine (HS-20093) for the treatment of small cell lung cancer has been included in the priority review and approval process of the National Medical Products Administration.
2026-09-14

Tencent Licaitong (current+) 7-day annualized yield range: 0.7340%–1.1512%. WeChat Lingqian Tong 7-day annualized 7-day yield range: 0.8620%–0.9690%. Alipay Yu’e Bao 7-day annualized yield range: 0.9010%–1.0140%.

Tencent Licaitong (current+) 7-day annualized yield range: 0.7340%–1.1512%. WeChat Lingqian Tong 7-day annualized 7-day yield range: 0.8620%–0.9690%. Alipay Yu’e Bao 7-day annualized yield range: 0.9010%–1.0140%.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.